iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response
Insight Molecular Diagnostics says it will answer the FDA's request for more clinical validation information on its donor-derived cfDNA kit before the 21 January 2027 deadline.
Insight Molecular Diagnostics (iMDx) reported its third-quarter 2026 results on 16 November, with the status of its US regulatory submission for GraftAssureDx a central point. The company's headline revenue figure for the quarter was $559,000.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Insight Molecular Diagnostics Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.